Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Vebreltinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apollomics Presents Vebreltinib Data At ESMO Congress 2024
    Apollomics Presents Vebreltinib Data At ESMO Congress 2024

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946593/0/en/Apollomics-Presents-Vebreltinib-Data-in-Patients-with-Non-Small-Cell-Lung-Cancer-with-METex14-Skipping-Mutations-at-European-Society-for-Medical-Oncology-ESMO-Congress-2024.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Apollomics Reports Positive Data For Vebreltinib In Solid Tumors
    Apollomics Reports Positive Data For Vebreltinib In Solid Tumors

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929124/0/en/Apollomics-Announces-Positive-Preliminary-Data-of-Vebreltinib-in-Patients-with-Non-CNS-MET-Fusion-Solid-Tumors-from-its-Phase-2-SPARTA-Trial.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Apollomics: Vebreltinib Data At ASCO 2024
    Apollomics: Vebreltinib Data At ASCO 2024

    04 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/04/2893001/0/en/Apollomics-Announces-Vebreltinib-Data-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    04 Jun 2024
    Share Share
    Avistone: Vebreltinib Approved in China for Rare Brain Glioma
    Avistone: Vebreltinib Approved in China for Rare Brain Glioma

    25 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240425029482/en

    BUSINESSWIRE
    25 Apr 2024
    Share Share
    Apollomics' Vebreltinib Approved in China for MET+ Gliomas
    Apollomics' Vebreltinib Approved in China for MET+ Gliomas

    25 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/25/2869647/0/en/Apollomics-Announces-Approval-of-Vebreltinib-in-China-as-a-First-in-Class-Treatment-for-Gliomas-with-MET-Fusion-Gene.html

    GLOBENEWSWIRE
    25 Apr 2024
    Share Share
    Apollomics Presents Vebreltinib Data at AACR Annual Meeting
    Apollomics Presents Vebreltinib Data at AACR Annual Meeting

    10 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/10/2860624/0/en/Apollomics-Presents-Vebreltinib-Data-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    10 Apr 2024
    Share Share